Metacrine, a San Diego, CA-based biotechnology company, raised $36m in Series A financing.
Backers included Arch Venture Partners, EcoR1 Capital, Polaris Partners and venBio.
Led by chief executive officer Neil McDonnell, Executive Chairman Richard Heyman, and co-founders Ronald Evans and Michael Downes, Metacrine focuses on targeting metabolic disease through advances in endocrine research.
The company is advancing technology licensed from the laboratory of Ronald Evans, a world leader in nuclear hormone receptors and Howard Hughes Medical Institute Investigator and director of the Gene Expression Laboratory at the Salk Institute, to develop two classes of novel therapeutics, to target diabetes, non-alcoholic steatohepatitis (NASH) and other metabolic diseases and liver disorders.
The Metacrine’s leadership team also includes Trisha Millican, chief financial officer; Nicholas Smith, Ph.D., senior vice president, chemistry; and Eric Bischoff, vice president, business operations.